XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.87

-1.4%

Jan 22 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (10774)	7/13/1999 9:31:00 PM
From: aknahow	Read Replies (1) of 17367

Cacaito, explained why we can't count on an even 50/50 split. but for analysis or speculation on results one ends up putting the same number in each arm. Look, here is how I see the impact of the SOC in the U.K. The bottle tumbler test gets lots of aware parents to get there kids treated fast. Attending docs. carry the antibiotic most used. The less aware barely get their kids in before they die and many of them did. Perhaps someday we will se how many of the 62 were from the U.K and how many from Canada/U.S. Such a hypothesis would lower the mortality rate. When adjusted for the 62 the mortality rate climbs to over 30% and even when one assumes there were another 62 who refused to enter the trial and lived the mortality rate still remains at 25% for those not treated with Neuprex. 79/259 or 79/321 Note that in both cases only 17 of the total deaths of those enrolled in the trial are assigned to the placebo arm, so if Neuprex worked the death rate for those not getting Neuprex is higher.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next